Table 2. Clinical Activity of DCA.

Outcome data is limited by small numbers of patients. Data regarding days on study, dose modifications or delays and best response to therapy are shown.

Subject	# Days on Study	Dose Reduction Required?	Best Response on DCA	Dose Delay (Reason)
Breast Cancer 1	72 Days	No	stable disease	No
NSCLC 1	7 Days	No	patient withdrew consent	Yes (Grade 3 Right Leg Swelling*)
NSCLC 2	46 Days	No	disease progression	Yes (Grade 3 Elevated AST**)
NSCLC 3	12 Days	No	patient withdrew consent	No
NSCLC 4	57 Days	No	disease progression	Yes (Grade 2 Tremors)
NSCLC 5	4 Days	No	death	No
NSCLC 6	7 Days	No	death	No
Mean # Days on Study	29.3 Days
Median # Days on Study	12 Days

^*Leg swelling not likely related to DCA

^**Elevated AST likely due to progression of liver metastases and not DCA